Letrozole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Letrozole: From Postmenopausal ER+ Breast Cancer to Female Breast Carcinoma
One-Sentence Summary
Letrozole is a third-generation aromatase inhibitor whose established, internationally approved use is hormone receptor-positive (ER+) breast cancer in postmenopausal women. The TxGNN model's top prediction for this drug is female breast carcinoma — effectively confirming its own existing indication rather than identifying a genuinely new one — and this is supported by 50 clinical trials (including several landmark Phase 3 studies) and 20 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from New Zealand regulatory data (drug is not currently licensed there). Per the drug's internationally established use — referenced throughout the evidence pack's own literature and trial titles — letrozole is approved for postmenopausal, hormone receptor-positive (ER+) breast cancer. |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L1 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank-sourced mechanism-of-action data was not available for this evidence pack (flagged as a High-severity data gap). However, the literature captured in the evidence pack itself is consistent and unambiguous: letrozole is a third-generation, non-steroidal aromatase inhibitor that blocks peripheral conversion of androgens to estrogens, thereby depriving estrogen receptor-positive (ER+) tumor cells of the hormonal signal that drives their proliferation (PMID 17912633, "The discovery and mechanism of action of letrozole"; PMID 20095792).
Because this mechanism acts directly on the estrogen-dependence of ER+ breast tumors, the drug's original approved use and TxGNN's predicted indication are, in this case, the same underlying disease population — this is not really a "repurposing" candidate in the traditional sense. As the evidence pack's own scoring rationale states, this is "letrozole's original approved indication (postmenopausal ER+ breast cancer), not a repurposing but an already-established standard of care."
The practical value of this prediction is therefore not scientific novelty but regulatory/market relevance: letrozole is currently unlicensed in New Zealand (0 authorizations, "not marketed" status), so the TxGNN-flagged evidence base functions as a ready-made dossier supporting a first-time market-entry filing for an indication with an exceptionally mature global evidence base (landmark trials date back to 1998).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00004205 | Phase 3 | Completed | 8,028 | Landmark BIG 1-98-type trial comparing letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal ER/PgR+ breast cancer. |
| NCT01626222 | Phase 3 | Completed | 301 | Everolimus + exemestane in postmenopausal ER+ breast cancer progressing after non-steroidal aromatase inhibitor therapy; graded A relevance. |
| NCT02296801 | Phase 2 (randomized) | Completed | 307 | Palbociclib + letrozole as neoadjuvant therapy in ER+/HER2- primary breast cancer; foundational study for the now-standard CDK4/6i + AI combination. |
| NCT00171340 | Phase 3 | Completed | 1,065 | Upfront vs. delayed zoledronic acid to prevent bone loss in postmenopausal ER/PgR+ patients on adjuvant letrozole. |
| NCT00171314 | Phase 3 | Completed | 527 | Companion trial evaluating zoledronic acid timing to prevent letrozole-associated bone loss. |
| NCT01064635 | Phase 3 | Active, not recruiting | 2,056 | LEAD study comparing standard vs. extended-duration adjuvant letrozole in early postmenopausal breast cancer. |
| NCT00382070 | Phase 3 | Unknown | 3,966 | Extended (5-year) letrozole vs. placebo after prior AI/tamoxifen sequence, assessing disease-free survival. |
| NCT04964934 | Phase 3 | Active, not recruiting | 315 | Switching to next-generation oral SERD + CDK4/6i vs. continuing AI (letrozole/anastrozole) + CDK4/6i in ESR1-mutated HR+/HER2- metastatic disease. |
| NCT03248427 | Phase 2 | Completed | 106 | CORALLEEN: neoadjuvant letrozole + ribociclib vs. chemotherapy in postmenopausal Luminal B/HER2- breast cancer. |
| NCT00097344 | Phase 3 | Terminated | 842 | Atamestane + toremifene vs. letrozole in advanced breast cancer; large sample despite early termination. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16382061 | 2005 | RCT | New England Journal of Medicine | BIG 1-98 trial: letrozole superior to tamoxifen as adjuvant treatment for postmenopausal hormone-receptor-positive early breast cancer. |
| 15001182 | 2004 | RCT | Women's Health Issues | Clinical implications and remaining questions from the Letrozole Breast Cancer Trial. |
| 36243120 | 2022 | Review | Life Sciences | Comprehensive review of letrozole pharmacology, toxicity, and therapeutic effects across HR+ breast cancer settings. |
| 35378469 | 2022 | Cohort | Current Problems in Cancer | Predictive and prognostic factors of response to palbociclib + letrozole in HR+/HER2- advanced breast cancer. |
| 20095792 | 2010 | Review | Expert Opinion on Drug Metabolism & Toxicology | Pharmacodynamic, pharmacokinetic, efficacy, and safety review of letrozole in breast cancer. |
| 17912633 | 2007 | Review | Breast Cancer Research and Treatment | Discovery and mechanism of action of letrozole as an aromatase inhibitor. |
| 19445563 | 2009 | Review | Expert Opinion on Pharmacotherapy | Comparative review of anastrozole, letrozole, and exemestane in early breast cancer management. |
| 22738819 | 2012 | Systematic Review | Current Medical Research and Opinion | Lapatinib + letrozole vs. other first-line treatments in HR+/HER2+ advanced/metastatic breast cancer. |
| 34645649 | 2022 | Study | Clinical Cancer Research | Biomarkers of response and resistance to palbociclib plus letrozole in ER+/HER2- breast cancer. |
| 41519129 | 2026 | Study | Cell Reports Medicine | NeoPAL trial: molecular and cellular composition changes after neoadjuvant letrozole + palbociclib in early luminal breast cancer. |
New Zealand Market Information
Letrozole currently has zero registered authorizations in New Zealand (market_status: 未上市 / not marketed; total_licenses: 0). No license records are available to tabulate.
Cytotoxicity
Letrozole is used to treat a malignant condition (breast carcinoma) and is classified under antineoplastic/endocrine therapy agents, so this section is included per protocol — though pharmacologically it is a targeted hormonal agent, not a conventional cytotoxic chemotherapy drug.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Endocrine (hormonal) therapy — non-cytotoxic aromatase inhibitor, not a conventional cytotoxic chemotherapeutic |
| Myelosuppression Risk | Low — aromatase inhibitors are not characteristically myelosuppressive; no specific hematologic toxicity data was returned in this evidence pack (DDI query: not found). Please refer to the package insert for confirmation. |
| Emetogenicity Classification | Low — consistent with the general emetogenic profile of hormonal/endocrine anticancer agents |
| Monitoring Items | Bone mineral density (long-term use is associated with bone loss — see zoledronic acid co-administration trials above), lipid profile, liver function |
| Handling Protection | Standard oral solid-dose handling; not classified as a hazardous cytotoxic drug requiring special handling precautions under typical chemotherapy-handling protocols — confirm against local institutional hazardous drug list |
Safety Considerations
Please refer to the package insert for safety information. (No key warnings, contraindications, or drug-interaction data were returned for letrozole in this evidence pack — TFDA package insert retrieval is flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The clinical and literature evidence base for letrozole in ER+ breast cancer is exceptionally mature (L1, ≥2 completed Phase 3 RCTs including a landmark >8,000-patient trial), but this "prediction" essentially reconfirms letrozole's own long-established global indication rather than surfacing a novel therapeutic use. The genuine open question is not efficacy but New Zealand market status: the drug holds zero current authorizations there, so any path forward is a market-entry/regulatory exercise rather than a repurposing R&D question.
To proceed, the following is needed:
- TFDA/Medsafe package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank — currently a High-severity data gap (DG002)
- Formal New Zealand regulatory filing pathway assessment, given the drug's current unlicensed status
- Drug-drug interaction profile (current DDI query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.